Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | GABRP | O00591 | 1/20 | 0.68 |
| ▸ | GABRD | O14764 | 1/20 | 0.68 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.68 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.68 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.68 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.68 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.68 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.68 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.68 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361219 | 0.89 | TP53 (0.72) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL5354863 | 0.88 | TP53 (0.71) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL5355886 | 0.88 | OPRK1 (0.73) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL3579580 | 0.88 | OPRK1 (0.73) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL27562818 | 0.86 | NPSR1 (0.78) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL9039066 | 0.86 | CYP1A2 (0.75) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL5361417 | 0.86 | OPRK1 (0.72) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL9040148 | 0.86 | OPRK1 (0.71) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL11855695 | 0.85 | OPRK1 (0.69) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| Prazepam SCHEMBL78272 | 0.85 | OPRK1 (0.69) | TP53OPRK1NR1I2ADORA3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238685-B2 | Benzo-fused heterocycles as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-03 | — | — | US | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
| US-4090027-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4077978-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-3996374-A | Isoindole derivatives as appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | TP53 3952/4885OPRK1 222/4885NR1I2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.